GoodRx Holdings, Inc.
NASDAQ:GDRXMedical - Healthcare Information Services
+$0.05 today
- Market cap
- $1.15B
- Beta
- 1.61
- P/E (TTM)
- 44.0
- EPS (TTM)
- $0.06
Volume 0.66M
Average 1.61M
GDRX Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
GoodRx Holdings, Inc.NASDAQ: GDRX
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development declines year over year
Q1 FY2026 research & development of $30.18M fell 3.1% year over year, in line with the -3.1% change in trailing-twelve-month research & development. Sequentially, it rose 4.3% from the prior quarter. Over 3 fiscal years it compounded at -5.4% a year.
Context
- Research & development amounted to 15.2% of revenue in FY2025, down 0.4 pp from a year earlier.
- Research & development increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -3.1% toward the trailing-twelve-month pace of -3.1%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 121.03M USD
- Year-over-year change
- -2.2%
- 4-year CAGR
- -1.0%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 121.03M | -2.2% |
| FY2024 | 2024-12-31 | 123.75M | -8.9% |
| FY2023 | 2023-12-31 | 135.84M | -5.1% |
| FY2022 | 2022-12-31 | 143.14M | +13.7% |
| FY2021 | 2021-12-31 | 125.86M | — |
Research & Development vs competitors
How GDRX compares with its peers on the latest reported figures
- GDRX's LTM Mar 2026 research & development of $120.06M is the 2nd highest of the 4 companies compared; the peer median is $63.14M.
- Its year-over-year change of -3.1% is the 2nd highest of 4, against a peer median of -22.5%.
- Research & development amounts to 15.2% of revenue for GDRX, versus a peer median of 12.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $320.12M | +4.5% | -5.9% | 12.7% | |
| LTM Mar 2026 | $120.06M | -3.1% | -5.4% | 15.2% | |
| LTM Mar 2026 | $63.14M | -22.5% | -19.3% | 26.6% | |
| LTM Mar 2026 | $7.53M | -25.4% | +35.2% | 3.4% | |
| Peer median (excluding GDRX) | $63.14M | -22.5% | -5.9% | 12.7% | |
Competitors are the stored peer set for GDRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 745.42M | 766.55M | 750.27M | 792.32M | 796.85M |
| Cost of Revenue | 46.72M | 65.08M | 66.93M | 48.22M | 57.6M |
| Gross Profit | 698.71M | 701.48M | 683.34M | 744.11M | 739.26M |
| Gross Margin | 93.7% | 91.5% | 91.1% | 93.9% | 92.8% |
| Research & Development | 125.86M | 143.14M | 135.84M | 123.75M | 121.03M |
| Selling, General & Admin | 524.9M | 502.42M | 466.84M | 484.98M | 445.52M |
| Operating Expenses | 685.3M | 699.74M | 710.35M | 678.26M | 651.76M |
| Depreciation & Amortization | 34.54M | 54.18M | 107.67M | 69.54M | 85.22M |
| EBITDA | 48M | 65.19M | 108.82M | 153.92M | 184.36M |
| EBITDA Margin | 6.4% | 8.5% | 14.5% | 19.4% | 23.1% |
| Operating Income | 13.41M | 1.74M | (27.01M) | 65.85M | 87.49M |
| Operating Margin | 1.8% | 0.2% | -3.6% | 8.3% | 11.0% |
| Interest Income | 59K | 9.27M | 32.17M | 23.27M | 10.93M |
| Interest Expense | 23.64M | 34.24M | 56.73M | 52.92M | 42.61M |
| Other Income / Expenses | (23.58M) | (24.97M) | (28.57M) | (34.39M) | (30.95M) |
| Income Before Tax | (10.18M) | (23.23M) | (55.57M) | 31.46M | 56.54M |
| Pre-Tax Margin | -1.4% | -3.0% | -7.4% | 4.0% | 7.1% |
| Income Tax Expense | 15.08M | 9.6M | (46.7M) | 15.07M | 26.1M |
| Net Income | (25.25M) | (32.83M) | (8.87M) | 16.39M | 30.44M |
| Net Margin | -3.4% | -4.3% | -1.2% | 2.1% | 3.8% |
| EPS (Basic) | (0.06) | (0.08) | (0.02) | 0.04 | 0.09 |
| EPS (Diluted) | (0.06) | (0.08) | (0.02) | 0.04 | 0.09 |
| Weighted Avg Shares | 409.98M | 412.86M | 410.32M | 385.74M | 356.33M |
| Weighted Avg Shares (Diluted) | 409.98M | 412.86M | 410.32M | 392.17M | 356.97M |
GoodRx Holdings, Inc.
NASDAQ:GDRX
Intrinsic Alpha fair value
Locked
Current Price
$3.36
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.